



## Alliance *for* Lupus Research

PREVENT. TREAT. CURE.

### OUR RESEARCH FUNDING MECHANISMS:

Target Identification in Lupus Grant	Functional Genomics and Molecular Pathways (FGMP) in SLE Grant	International SLE Genetics Initiative (SLEGEN)
<p>Under our Target Identification in Lupus (TIL) grant program, investigators leverage a two-year, up-to-\$400,000 award to remove the barriers to new treatments and a possible cure. Researchers also have the opportunity to apply for continued funding up to \$200,000. All lupus research funded under the TIL program is based on realizable goals for translation into therapeutic discovery programs – that is, research that can move quickly from the laboratory to the patient’s bedside.</p>	<p>Under our FGMP Grant, investigators receive Research grants of up to \$350,000 for two years or Pilot Grants of up to \$75,000 for one year. Grantees will focus on determining how the genes identified as a result of the SLEGEN Initiative may have a role in lupus, and provide further information about the molecular pathways modulated by these genes.</p>	<p>Launched in 2005, this special initiative is designed to accelerate the search for genes that put people at risk for developing systemic lupus erythematosus (SLE or lupus). The SLEGEN Initiative facilitates this by pooling patient samples collected from the International SLE Genetics Consortium, which includes many scientists working on the genetics of lupus.</p>

**Since its founding, the *Alliance for Lupus Research* (ALR) has given more money to lupus research than any non-governmental agency in the world.**

**To date, the ALR has committed over \$67 million to lupus research.**

*If you have any questions about any of the above, please contact **Diomaris Gonzalez**, Assistant Director of Research Administration at [dgonzalez@lupusresearch.org](mailto:dgonzalez@lupusresearch.org) or 212-218-2840.*

TIL and TIL Renewal Grants - 2010			
Investigator	Institution	State	Project Title
Eisenberg, Robert, MD	The University of Pennsylvania	PA	Distal Ig Receptor Revision in the Production of SLE Autoantibodies
Elkon, Keith, MD	University of Washington	WA	Lysis of Immunostimulatory Nucleoproteins in SLE
Jacob, Chaim, MD, PhD	USC/University of Southern California	CA	Targeted DNA capture and parallel sequencing to identify causal mutation
Kelley, Vicki, PhD	Brigham and Women's Hospital, Inc.	MA	Colony Stimulating Factor 1: A Therapeutic Target for Lupus Nephritis
Lu, Kun Ping, MD, PhD	Beth Israel Deaconess Medical Center	MA	The prolyl isomerase Pin1: a novel therapeutic target in SLE
Niewold, Timothy, MD	The University of Chicago	IL	Role of ILT Receptors in Human Lupus
Perl, Andras, MD, PhD	SUNY Upstate Medical University	NY	Mitochondrial Hyperpolarization in Lupus T Cells
Rifkin, Ian, MD, PhD	Boston Medical Center Corporation	MA	Adiponectin and adiponectin receptors in lupus and lupus atherosclerosis
TIL Grants - 2011			
Barnes, Betsy, PhD	UMDNJ-New Jersey Medical School	NJ	Targeting IRF5 activation for the treatment of lupus
Craft, Joseph, MD	Yale University	NJ	Follicular Helper T Cells in SLE: Characterization and Therapeutic Targets
Datta, Syamal, MBBS	Northwestern University - Chicago Campus	IL	Peptide Vaccine Suppressing Autoantigen-Specific Response in Human Lupus
Denny, Michael, PhD	Temple University	PA	Abnormal Neutrophil Development in SLE
Diamond, Betty, MD	The Feinstein Institute for Medical Research	NY	Dendritic cell dysfunction as a path to SLE
Fu, Shu Man, MD, PhD	University of Virginia	VA	Progressions and Biomarkers of Proliferative Lupus Nephritis
Jefferies, Caroline, PhD	Royal College of Surgeons in Ireland	--	Ro52 and Siglec-E as therapeutic targets in SLE
Kaplan, Mariana, MD	University of Michigan	MI	Lupus and the inflammasome
Pillai, Shiv, PhD, MBBS	Massachusetts General Hospital	MA	Targeting the SIAE pathway in lupus
Pisetsky, David, MD, PhD	Duke University Medical Center	NC	Nucleic Acid Binding Polymers in the Treatment for SLE
Sharma, Shruty, PhD	University of Massachusetts Medical School	MA	Innate sensing of AT-rich DNA during autoimmunity
Functional Genomics and Molecular Pathways (FGMP) in SLE Grants - 2010			
Alarcon-Riquelme, Marta, MD, PhD	Oklahoma Medical Research Foundation	OK	Dissecting a Novel Molecular Genetic B-Cell Pathway in Lupus
Clancy, Robert, PhD	New York University School of Medicine	NY	ITGAM R77H: Genotype/Phenotype Relationships in Dendritic Cells
Ho, I-Cheng, MD, PhD	Brigham and Women's Hospital, Inc.	MA	Protective roles of Ets1 in SLE
Perrino, Fred, PhD	Wake Forest University Health Sciences	NC	TREX1 mutations in SLE
Silverman, Earl, MD	The Hospital for Sick Children (Canada)	--	How Genes determine SLE Phenotype and Outcome
Yan, Jun, MD, PhD	University of Louisville	KY	Regulation of Autoreactive B Cells by Integrin ITGAM/CD11b
Functional Genomics and Molecular Pathways (FGMP) in SLE Grants - 2011			
Atkinson, John, MD	Washington University School of Medicine	MO	Complement Mutations in End Stage Renal Disease Lupus Patients
Criswell, Lindsey Ann, MD, PhD	The Regents of the University of California - San Francisco	CA	Functional Genomics and Pathway Analysis of the MCH Region in SLE
Crow, Yanick, PhD	University of Manchester	Manchester, UK	Pathways Linking Tartrate Resistant Acid Phosphatase, Interferon, and Lupus
Roopenian, Derry, PhD	The Jackson Laboratory	ME	Novel Approach to Modeling the Functional Genomics of Human SLE in Mice
Satterthwaite, Anne, PhD	University of Texas Southwestern Medical Center	TX	Functional Relationships Between the Lupus Susceptibility Loci Lyn and Ets1
Siminovitch, Katherine, MD	University Health Network	Toronto, Canada	Defining Functional Implications of a Human SLE Risk Allele in Mice
SLEGEN Consortium - 2011			
ImmunoChip	University of Alabama at Birmingham	AL	SLE Genetics Consortium